(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Canopy Growth, Aurora Cannabis, and SNDL Inc..

The three biggest losers today are Beasley Broadcast Group, Sphere 3D Corp., and Canaan.

Winners today

1. Canopy Growth (CGC) – 68.64%

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flower, extracts and concentrates, beverages, gummies, and vapes. It offers its products under the Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

NASDAQ ended the session with Canopy Growth jumping 68.64% to $7.69 on Friday while NASDAQ rose 0.16% to $16,428.82.

Earnings Per Share

As for profitability, Canopy Growth has a trailing twelve months EPS of $-15.69.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -121.56%.

More news about Canopy Growth.

2. Aurora Cannabis (ACB) – 26.56%

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

NYSE ended the session with Aurora Cannabis jumping 26.56% to $4.86 on Friday while NYSE slid 0.56% to $18,112.04.

Earnings Per Share

As for profitability, Aurora Cannabis has a trailing twelve months EPS of $-58.35.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -102.67%.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 84.6% and 86.7%, respectively.

Volume

Today’s last reported volume for Aurora Cannabis is 13109100 which is 1102.26% above its average volume of 1090380.

Moving Average

Aurora Cannabis’s worth is way higher than its 50-day moving average of $0.47 and way higher than its 200-day moving average of $0.54.

Yearly Top and Bottom Value

Aurora Cannabis’s stock is valued at $4.86 at 17:32 EST, way higher than its 52-week high of $1.21.

More news about Aurora Cannabis.

3. SNDL Inc. (SNDL) – 21.18%

SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through four segments: Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. The company also produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.

NASDAQ ended the session with SNDL Inc. jumping 21.18% to $1.75 on Friday while NASDAQ jumped 0.16% to $16,428.82.

Earnings Per Share

As for profitability, SNDL Inc. has a trailing twelve months EPS of $-0.64.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -17.6%.

Yearly Top and Bottom Value

SNDL Inc.’s stock is valued at $1.75 at 17:32 EST, way under its 52-week high of $2.36 and way higher than its 52-week low of $1.25.

Volatility

SNDL Inc.’s last week, last month’s, and last quarter’s current intraday variation average was 4.56%, 0.86%, and 2.94%.

SNDL Inc.’s highest amplitude of average volatility was 4.56% (last week), 2.77% (last month), and 2.94% (last quarter).

Earnings Before Interest, Taxes, Depreciation, and Amortization

SNDL Inc.’s EBITDA is -130.36.

Volume

Today’s last reported volume for SNDL Inc. is 17681800 which is 439.24% above its average volume of 3279020.

More news about SNDL Inc..

4. Tilray (TLRY) – 18.46%

Tilray Brands, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. It also offers medical and adult-use cannabis products; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products. In addition, the company offers its products under the Tilray, Aphria, Broken Coast, Symbios, B!NGO, The Batch, Dubon, Good Supply, Solei, Chowie Wowie, Canaca, RIFF, SweetWater, Breckenridge Distillery, Alpine Beer Company, and Green Flash brands. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. and changed its name to Tilray Brands, Inc. in January 2022. Tilray Brands, Inc. is headquartered in Leamington, Canada.

NASDAQ ended the session with Tilray rising 18.46% to $2.31 on Friday, following the last session’s downward trend. NASDAQ rose 0.16% to $16,428.82, after four successive sessions in a row of gains, on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, Tilray has a trailing twelve months EPS of $-2.28.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -36%.

More news about Tilray.

5. Comstock Holding Companies (CHCI) – 11.83%

Comstock Holding Companies, Inc. develops, operates, and manages of mixed-use and transit-oriented properties primarily in the Washington, D.C. metropolitan area. The company operates a portfolio of 34 operating assets, which include 14 commercial assets totaling approximately 2.2 million square feet; 6 multifamily assets totaling 1,636 units; and 14 commercial garages with approximately 11,000 parking spaces. It also has 18 development pipeline assets consisting of approximately 2.0 million square feet of additional planned commercial development; approximately 1,900 multifamily units; and 2 hotel assets. In addition, the company provides real estate development and management services. It primarily serves private and institutional owners; investors in commercial, residential, and mixed-use real estate; and various governmental bodies. The company was formerly known as Comstock Homebuilding Companies, Inc. and changed its name to Comstock Holding Companies, Inc. in June 2012. Comstock Holding Companies, Inc. was founded in 1985 and is headquartered in Reston, Virginia.

NASDAQ ended the session with Comstock Holding Companies jumping 11.83% to $5.20 on Friday while NASDAQ jumped 0.16% to $16,428.82.

Earnings Per Share

As for profitability, Comstock Holding Companies has a trailing twelve months EPS of $0.71.

PE Ratio

Comstock Holding Companies has a trailing twelve months price to earnings ratio of 7.32. Meaning, the purchaser of the share is investing $7.32 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.56%.

Volume

Today’s last reported volume for Comstock Holding Companies is 40358 which is 807.94% above its average volume of 4445.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Comstock Holding Companies’s EBITDA is 8.72.

Yearly Top and Bottom Value

Comstock Holding Companies’s stock is valued at $5.20 at 17:32 EST, way below its 52-week high of $6.54 and way higher than its 52-week low of $3.47.

More news about Comstock Holding Companies.

6. CalAmp Corp. (CAMP) – 9.97%

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location. The company also offers telematics products, including asset tracking units, mobile telematics devices, fixed and mobile wireless gateways, and routers; and advanced telematics products for the broader connected vehicle and Internet of Things marketplace, which enable customers to optimize their operations by collecting, monitoring, and reporting business-critical information and desired intelligence from remote and mobile assets. In addition, it offers professional services, including project management, engineering services, and installation services. The company sells its products and services to customers in the automotive, telecommunications, industrial equipment, transportation and logistics, government and municipalities, insurance, auto dealers, original equipment manufacturers, and leasing companies. It markets through direct sales organization, channel partner program, original equipment manufacturers, and independent sales representatives and distributors, as well as its websites and digital platform. The company was incorporated in 1981 and is headquartered in Irvine, California.

NASDAQ ended the session with CalAmp Corp. rising 9.97% to $3.31 on Friday while NASDAQ rose 0.16% to $16,428.82.

Earnings Per Share

As for profitability, CalAmp Corp. has a trailing twelve months EPS of $-63.02.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is a negative 247.8% and a negative 600%, respectively.

Revenue Growth

Year-on-year quarterly revenue growth declined by 32%, now sitting on 264.74M for the twelve trailing months.

More news about CalAmp Corp..

7. Cronos Group (CRON) – 9.21%

Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones brand in the United States. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. It sells cannabis and cannabis products, including dried cannabis, pre-rolls, edibles, concentrates, and cannabis extracts through wholesale and direct-to-client channels under its wellness platform, PEACE NATURALS; and operates under adult-use brands, Spinach. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

NASDAQ ended the session with Cronos Group rising 9.21% to $2.61 on Friday, after five successive sessions in a row of gains. NASDAQ jumped 0.16% to $16,428.82, after four successive sessions in a row of gains, on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, Cronos Group has a trailing twelve months EPS of $-0.18.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -6.3%.

Yearly Top and Bottom Value

Cronos Group’s stock is valued at $2.61 at 17:32 EST, under its 52-week high of $2.64 and way higher than its 52-week low of $1.64.

Volatility

Cronos Group’s last week, last month’s, and last quarter’s current intraday variation average was 3.98%, 0.32%, and 2.45%.

Cronos Group’s highest amplitude of average volatility was 3.98% (last week), 2.33% (last month), and 2.45% (last quarter).

More news about Cronos Group.

8. AXT (AXTI) – 8.22%

AXT, Inc. designs, develops, manufactures, and distributes compound and single element semiconductor substrates. It produces semiconductor substrates using its proprietary vertical gradient freeze technology. The company offers indium phosphide for use in data center connectivity using light/lasers, 5G communications, fiber optic lasers and detectors, passive optical networks, silicon photonics, photonic integrated circuits, terrestrial solar cells, RF amplifier and switching, infrared light-emitting diode (LEDS) motion control, lidar for robotics and autonomous vehicles, and infrared thermal imaging. It also provides semi-insulating gallium arsenide (GaAs) substrates for use in Wi-Fi and IoT devices, transistors, direct broadcast television, power amplifiers, satellite communications, and solar cells; and semi-conducting GaAs substrates that are used in LED, screen displays, printer head lasers and LEDs, 3-D sensing using VCSELs, data center communication using VCSELs, sensors for industrial robotics/near-infrared sensors, optical couplers, solar cells, night vision goggles, lidar for robotics and autonomous vehicles, and other lasers, as well as laser machining, cutting, and drilling. In addition, the company offers germanium substrates for use in multi-junction solar cells for satellites, optical sensors and detectors, terrestrial concentrated photo voltaic cells, infrared detectors, and carrier wafer for LED. Further, it provides 6N+ and 7N+ purified gallium, boron trioxide, gallium-magnesium alloy, pyrolytic boron nitride (pBN) crucibles, and pBN insulating parts. AXT, Inc. sells its products through direct salesforce in the United States, China, and Europe, as well as through independent sales representatives and distributors in Japan, Taiwan, Korea, and internationally. The company was formerly known as American Xtal Technology, Inc. and changed its name to AXT, Inc. in July 2000. AXT, Inc. was incorporated in 1986 and is headquartered in Fremont, California.

NASDAQ ended the session with AXT rising 8.22% to $5.40 on Friday, after two sequential sessions in a row of gains. NASDAQ jumped 0.16% to $16,428.82, after four consecutive sessions in a row of gains, on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, AXT has a trailing twelve months EPS of $-0.42.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -6.87%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 23.8%, now sitting on 75.8M for the twelve trailing months.

Earnings Before Interest, Taxes, Depreciation, and Amortization

AXT’s EBITDA is 3.41.

More news about AXT.

9. FedEx (FDX) – 7.35%

FedEx Corporation provides transportation, e-commerce, and business services in the United States and internationally. It operates through FedEx Express, FedEx Ground, FedEx Freight, and FedEx Services segments. The FedEx Express segment offers express transportation, small-package ground delivery, and freight transportation services; and time-critical transportation services. The FedEx Ground segment provides small-package ground delivery services. The FedEx Freight segment offers less-than-truckload freight transportation services. The FedEx Services segment provides sales, marketing, information technology, communications, customer service, technical support, billing and collection, and back-office support services. In addition, the company offers supply chain management solutions; and air and ocean cargo transportation, specialty transportation, customs brokerage, and trade management tools and data. The company was founded in 1971 and is headquartered in Memphis, Tennessee.

NYSE ended the session with FedEx rising 7.35% to $284.32 on Friday, after three sequential sessions in a row of gains. NYSE fell 0.56% to $18,112.04, after four sequential sessions in a row of gains, on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, FedEx has a trailing twelve months EPS of $17.32.

PE Ratio

FedEx has a trailing twelve months price to earnings ratio of 16.42. Meaning, the purchaser of the share is investing $16.42 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.85%.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on Mar 8, 2024, the estimated forward annual dividend rate is 5.04 and the estimated forward annual dividend yield is 2.03%.

Previous days news about FedEx

• Fedex (fdx) tops Q3 earnings estimates. According to Zacks on Thursday, 21 March, "While FedEx has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?"
• Fedex (fdx) reports Q3 earnings: what key metrics have to say. According to Zacks on Thursday, 21 March, "For the quarter ended February 2024, FedEx (FDX Quick QuoteFDX – Free Report) reported revenue of $21.7 billion, down 2.1% over the same period last year. ", "Here is how FedEx performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:"

More news about FedEx.

10. Ascent Solar Technologies (ASTI) – 6.41%

Ascent Solar Technologies, Inc. designs, manufactures, and sells copper-indium-gallium-diselenide photovoltaic products for aerospace, defense, emergency management, and consumer/OEM applications. It offers outdoor solar chargers. The company markets and sells its products through OEMs, system integrators, distributors, retailers, and e-commerce companies. Ascent Solar Technologies, Inc. was incorporated in 2005 and is based in Thornton, Colorado.

NASDAQ ended the session with Ascent Solar Technologies jumping 6.41% to $0.42 on Friday, after five consecutive sessions in a row of gains. NASDAQ jumped 0.16% to $16,428.82, after four sequential sessions in a row of gains, on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, Ascent Solar Technologies has a trailing twelve months EPS of $-34.19.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1116.07%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Ascent Solar Technologies’s EBITDA is 9.63.

Moving Average

Ascent Solar Technologies’s worth is way under its 50-day moving average of $0.59 and way below its 200-day moving average of $6.89.

Volume

Today’s last reported volume for Ascent Solar Technologies is 864185 which is 29.29% above its average volume of 668393.

Revenue Growth

Year-on-year quarterly revenue growth declined by 78%, now sitting on 458.26k for the twelve trailing months.

More news about Ascent Solar Technologies.

Losers Today

1. Beasley Broadcast Group (BBGI) – -9.87%

Beasley Broadcast Group, Inc., a multi-platform media company, owns and operates radio stations in the United States. It also operates Houston Outlaws, an esports team that competes in the Overwatch League. The company was founded in 1961 and is headquartered in Naples, Florida.

NASDAQ ended the session with Beasley Broadcast Group sliding 9.87% to $0.80 on Friday, following the last session’s downward trend. NASDAQ rose 0.16% to $16,428.82, after four successive sessions in a row of gains, on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, Beasley Broadcast Group has a trailing twelve months EPS of $-2.51.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -40.34%.

Moving Average

Beasley Broadcast Group’s worth is below its 50-day moving average of $0.87 and way below its 200-day moving average of $0.89.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Beasley Broadcast Group’s EBITDA is 1.23.

Revenue Growth

Year-on-year quarterly revenue growth declined by 8.7%, now sitting on 247.11M for the twelve trailing months.

More news about Beasley Broadcast Group.

2. Sphere 3D Corp. (ANY) – -8.5%

Sphere 3D Corp. focuses on operating as a carbon neutral bitcoin mining company. It also provides data management solutions through hybrid cloud, cloud, and on-premises implementations directly and through its reseller network and professional services organization. Its products portfolio includes HVE-STACK high density server, which provides computer and storage appliance for the data centers; HVE-VELOCITY, a high availability dual enclosure storage area network that offers reliability and integrity for optimal data storage, protection, and recovery; HVE 3DGFX, a virtual desktop infrastructure solution; HVE STAGE, a server virtualization platform; and HVE VAULT, an appliance designed to handle requirements for backup and replication storage. In addition, it offers self-service and support services. Sphere 3D Corp. is based in Toronto, Canada.

NASDAQ ended the session with Sphere 3D Corp. dropping 8.5% to $1.40 on Friday, following the last session’s downward trend. NASDAQ rose 0.16% to $16,428.82, after four successive sessions in a row of gains, on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, Sphere 3D Corp. has a trailing twelve months EPS of $-1.93.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -41.9%.

More news about Sphere 3D Corp..

3. Canaan (CAN) – -8.39%

Canaan Inc. engages in the research, design, and sale of integrated circuit (IC) final mining equipment products by integrating IC products for bitcoin mining and related components in the People's Republic of China. It is also involved in the assembly and distribution of mining equipment and spare parts. The company has operations in the United States, Australia, Kazakhstan, Hong Kong, Canada, Mainland China, Thailand, Sweden, and internationally. Canaan Inc. was founded in 2013 and is based in Singapore.

NASDAQ ended the session with Canaan sliding 8.39% to $1.42 on Friday while NASDAQ jumped 0.16% to $16,428.82.

Earnings Per Share

As for profitability, Canaan has a trailing twelve months EPS of $-2.41.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -87.6%.

Moving Average

Canaan’s value is way below its 50-day moving average of $1.84 and way under its 200-day moving average of $2.04.

Sales Growth

Canaan’s sales growth is negative 27% for the ongoing quarter and negative 14.5% for the next.

Yearly Top and Bottom Value

Canaan’s stock is valued at $1.42 at 17:32 EST, way under its 52-week high of $3.50 and way higher than its 52-week low of $1.13.

More news about Canaan.

4. Gevo (GEVO) – -7.62%

Gevo, Inc. operates as a carbon abatement company. It operates through three segments: Gevo, Agri-Energy, and Renewable Natural Gas. The company focuses on transforming renewable energy into energy-dense liquid hydrocarbons that can be used as renewable fuels. It offers renewable gasoline and diesel, isobutanol, sustainable aviation fuel, renewable natural gas, isobutylene, ethanol, and animal feed and protein. The company was formerly known as Methanotech, Inc. and changed its name to Gevo, Inc. in March 2006. Gevo, Inc. was incorporated in 2005 and is headquartered in Englewood, Colorado.

NASDAQ ended the session with Gevo falling 7.62% to $0.62 on Friday, following the last session’s downward trend. NASDAQ jumped 0.16% to $16,428.82, after four successive sessions in a row of gains, on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, Gevo has a trailing twelve months EPS of $-0.28.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -11.39%.

More news about Gevo.

5. Coherus BioSciences (CHRS) – -7.17%

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

NASDAQ ended the session with Coherus BioSciences sliding 7.17% to $2.33 on Friday, after three successive sessions in a row of gains. NASDAQ jumped 0.16% to $16,428.82, after four sequential sessions in a row of gains, on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, Coherus BioSciences has a trailing twelve months EPS of $-2.53.

More news about Coherus BioSciences.

6. BeiGene (BGNE) – -7.13%

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

NASDAQ ended the session with BeiGene dropping 7.13% to $152.02 on Friday while NASDAQ jumped 0.16% to $16,428.82.

Earnings Per Share

As for profitability, BeiGene has a trailing twelve months EPS of $-8.45.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -22.26%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 66.9%, now sitting on 2.46B for the twelve trailing months.

Volume

Today’s last reported volume for BeiGene is 443000 which is 47.37% above its average volume of 300590.

More news about BeiGene.

7. Atara Biotherapeutics (ATRA) – -7.08%

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

NASDAQ ended the session with Atara Biotherapeutics dropping 7.08% to $0.67 on Friday, following the last session’s downward trend. NASDAQ jumped 0.16% to $16,428.82, after four sequential sessions in a row of gains, on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, Atara Biotherapeutics has a trailing twelve months EPS of $-2.78.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -425.97%.

More news about Atara Biotherapeutics.

8. Nike (NKE) – -6.9%

NIKE, Inc., together with its subsidiaries, designs, develops, markets, and sells athletic footwear, apparel, equipment, accessories, and services worldwide. The company provides athletic and casual footwear, apparel, and accessories under the Jumpman trademark; and casual sneakers, apparel, and accessories under the Converse, Chuck Taylor, All Star, One Star, Star Chevron, and Jack Purcell trademarks. It also sells a line of performance equipment and accessories comprising bags, sport balls, socks, eyewear, timepieces, digital devices, bats, gloves, protective equipment, and other equipment for sports activities under the NIKE brand; and various plastic products to other manufacturers. In addition, the company markets apparel with licensed college and professional team, and league logos, as well as sells sports apparel; and licenses unaffiliated parties to manufacture and sell apparel, digital devices, and applications and other equipment for sports activities under NIKE-owned trademarks. It sells its products to footwear stores; sporting goods stores; athletic specialty stores; department stores; skate, tennis, and golf shops; and other retail accounts through NIKE-owned retail stores, digital platforms, independent distributors, licensees, and sales representatives. NIKE, Inc. was founded in 1964 and is headquartered in Beaverton, Oregon.

NYSE ended the session with Nike dropping 6.9% to $93.86 on Friday, after three successive sessions in a row of gains. NYSE slid 0.56% to $18,112.04, after four sequential sessions in a row of gains, on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, Nike has a trailing twelve months EPS of $3.43.

PE Ratio

Nike has a trailing twelve months price to earnings ratio of 27.36. Meaning, the purchaser of the share is investing $27.36 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 36.03%.

Sales Growth

Nike’s sales growth for the next quarter is 2.4%.

Previous days news about Nike

• Is Nike (nke) a buy heading into its upcoming earnings announcement?. According to Zacks on Thursday, 21 March, "Well-known athletic apparel maker Nike (NKE Quick QuoteNKE – Free Report) is set to report fiscal third-quarter results on Thursday after the bell. "

More news about Nike.

9. Astrotech Corporation (ASTC) – -6.81%

Astrotech Corporation operates as a mass spectrometry company worldwide. It owns and licenses the intellectual property related to the Astrotech Mass Spectrometer Technology, a platform mass spectrometry technology. The company also develops TRACER 1000, a mass spectrometer-based explosive trace detector to replace the explosives trace detectors used at airports, cargo and other secured facilities, and borders. In addition, it develops AgLAB-1000, a mass spectrometer for use in the hemp and cannabis market. Further, the company develops BreathTest-1000, a breath analysis tool to screen for volatile organic compound metabolites found in a person's breath. The company was formerly known as SPACEHAB, Inc. and changed its name to Astrotech Corporation in 2009. Astrotech Corporation was incorporated in 1984 and is based in Austin, Texas.

NASDAQ ended the session with Astrotech Corporation falling 6.81% to $8.08 on Friday, after four sequential sessions in a row of losses. NASDAQ jumped 0.16% to $16,428.82, after four successive sessions in a row of gains, on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, Astrotech Corporation has a trailing twelve months EPS of $-6.28.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -23.03%.

Yearly Top and Bottom Value

Astrotech Corporation’s stock is valued at $8.08 at 17:32 EST, way under its 52-week high of $15.11 and way above its 52-week low of $7.00.

More news about Astrotech Corporation.

10. Zai Lab (ZLAB) – -6.2%

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

NASDAQ ended the session with Zai Lab dropping 6.2% to $16.18 on Friday while NASDAQ rose 0.16% to $16,428.82.

Earnings Per Share

As for profitability, Zai Lab has a trailing twelve months EPS of $-3.5.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -36.34%.

Volatility

Zai Lab’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.42%, a negative 0.96%, and a positive 2.98%.

Zai Lab’s highest amplitude of average volatility was 3.12% (last week), 3.82% (last month), and 2.98% (last quarter).

Moving Average

Zai Lab’s value is way under its 50-day moving average of $22.33 and way below its 200-day moving average of $25.86.

More news about Zai Lab.

Stay up to date with our winners and losers daily report